HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Philippe Menasché Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azarnoush, K. Articles by Menasché, P. Search for Related Content PubMed PubMed Citation Articles by Azarnoush, K. Articles by Menasché, P. Related Collections Transplantation - heart

J Thorac Cardiovasc Surg 2005;130:173-179
© 2005 The American Association for Thoracic Surgery

Cardiothoracic Transplantation

Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1

^a INSERM, U 633, Laboratoire d’Etude des Greffes et Prothèses Cardiaques, Hôpital Broussais, Paris, France
^d U 582, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
^f U 430, Hôpital Broussais, Paris, France
^b Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, the Department of Cardiology, Paris, France
^g Department of Cardiovascular Surgery, Paris, France
^h Department of Pathology, Paris, France
^e Clinical Investigation Center/INSERM, Paris, France
^c University of Paris 5 Rene-Descartes, Paris, France

Received for publication June 4, 2004; revisions received October 27, 2004; accepted for publication November 2, 2004.

^_* Address for reprints: Philippe Menasché, MD, PhD, Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France. (Email: philippe.menasche{at}hop.egp.ap-hop-paris.fr).

OBJECTIVE: Early cell death remains a major limitation of skeletal myoblast transplantation. Because the poor vascularization of the target scars contributes to cell loss, we assessed the effects of combining skeletal myoblast transplantation with administration of hypoxia-inducible factor 1, a master gene that controls the expression of a wide array of angiogenic factors.

METHODS: A myocardial infarction was created in 56 rats by means of coronary artery ligation. Eight days later, rats were randomly allocated to receive in-scar injections of culture medium (control animals, n = 11), skeletal myoblasts (5 x 10⁶, n = 13), adenovirus-encoded hypoxia-inducible factor 1 (1.0 x 10¹⁰ pfu/mL, n = 7), or skeletal myoblasts (5 x 10⁶) in combination with an empty vector (n = 3) or active hypoxia-inducible factor 1 (1.0 x 10¹⁰ pfu/mL, n = 13). A fifth group (n = 9) underwent a staged approach in which hypoxia-inducible factor 1 (1.0 x 10¹⁰ pfu/mL) was injected at the time of infarction, followed 8 days later by skeletal myoblasts (5 x 10⁶). Left ventricular function was assessed echocardiographically before transplantation and 1 month thereafter. Explanted hearts were then processed for the immunohistochemical detection of myotubes, quantification of angiogenesis, myoblast engraftment, and cell survival.

RESULTS: Baseline ejection fractions were not significantly different among groups (35%–40%). One month later, ejection fraction had decreased from baseline in control hearts and in those injected with hypoxia-inducible factor 1. In contrast, it did not deteriorate after injections of skeletal myoblasts alone or combined with either the empty vector or active hypoxia-inducible factor 1 administered sequentially. The most striking change occurred in the skeletal myoblast plus hypoxia-inducible factor 1 combined group in which ejection fraction increased dramatically (by 27%) above baseline levels and was thus markedly higher than in all other groups (P = .0001 and P = .001 vs control animals and animals receiving hypoxia-inducible factor 1, respectively). Compared with skeletal myoblasts alone, the coadministration of hypoxia-inducible factor 1 resulted in a significantly greater degree of angiogenesis, cell engraftment, and cell survival.

CONCLUSION: Induction of angiogenesis is an effective means of potentiating the functional benefits of myoblast transplantation, and hypoxia-inducible factor 1 can successfully achieve this goal.

This article has been cited by other articles:

				J. J. Gavira, G. Abizanda, M. Perez-Ilzarbe, D. Martinez-Caro, E. Nasarre, A. Perez-Ruiz, and F. Prosper Skeletal myoblasts for cardiac repair in animal models Eur. Heart J. Suppl., December 1, 2008; 10(suppl_K): K11 - K15. [Abstract] [Full Text] [PDF]

				P. Menasche Towards the second generation of skeletal myoblasts? Cardiovasc Res, August 1, 2008; 79(3): 355 - 356. [Full Text] [PDF]

				S. Chanseaume, K. Azarnoush, A. Maurel, V. Bellamy, S. Peyrard, P. Bruneval, A. A. Hagege, and P. Menasche Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Interactive CardioVascular and Thoracic Surgery, June 1, 2007; 6(3): 293 - 297. [Abstract] [Full Text] [PDF]

				M. R. Abraham and G. Gerstenblith Preconditioning Stem Cells for Cardiovascular Disease: An Important Step Forward Circ. Res., March 2, 2007; 100(4): 447 - 449. [Full Text] [PDF]

				P. Menasche, M. Desnos, and A. A. Hagege Myoblast transplantation during cardiac surgery Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H52 - H56. [Abstract] [Full Text] [PDF]

				K. H. Wu, Y. L. Liu, B. Zhou, and Z. C. Han Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 770 - 781. [Abstract] [Full Text] [PDF]

				A. A. Hagege, J.-P. Marolleau, J.-T. Vilquin, A. Alheritiere, S. Peyrard, D. Duboc, E. Abergel, E. Messas, E. Mousseaux, K. Schwartz, et al. Skeletal Myoblast Transplantation in Ischemic Heart Failure: Long-Term Follow-Up of the First Phase I Cohort of Patients Circulation, July 4, 2006; 114(1_suppl): I-108 - I-113. [Abstract] [Full Text] [PDF]

				M. Siepe, M.-N. Giraud, M. Pavlovic, C. Receputo, F. Beyersdorf, P. Menasche, T. Carrel, and H. T. Tevaearai Myoblast-seeded biodegradable scaffolds to prevent post-myocardial infarction evolution toward heart failure J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 124 - 131. [Abstract] [Full Text] [PDF]

				S. Fernandes, J.-C. Amirault, G. Lande, J.-M. Nguyen, V. Forest, O. Bignolais, G. Lamirault, D. Heudes, J.-L. Orsonneau, M.-F. Heymann, et al. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias Cardiovasc Res, February 1, 2006; 69(2): 348 - 358. [Abstract] [Full Text] [PDF]